Wholesale peptide supply for telehealth platforms.
Bulk peptide API supplied to your partner 503A pharmacy. 503B finished-dose where the platform model supports a licensed clinical setting. Documentation packages built for both pharmacy QA and platform legal review — so the supply side is not the part of your business that breaks during scale.
How the telehealth channel works.
A telehealth platform is not our direct customer. The licensed pharmacy partner that operates as the dispensing entity for the platform is. We sell to the pharmacy under its license, the pharmacy compounds and dispenses on a valid prescription from the platform’s prescribing network, and the platform itself sits as an integration partner across the workflow.
This is not a workaround. It is the only structure that holds up to a state board of pharmacy review. Telehealth peptide programs that try to shortcut the pharmacy in the middle — supplier ships compounded product to a fulfillment warehouse, platform “ships” to consumer — do not survive a regulator’s second look. We do not support that model.
What we need a platform to have in place.
Before we open a supply relationship to a platform’s partner pharmacy, we want to see:
- A partner 503A pharmacy with appropriate state licensure. The pharmacy is the actual customer; it has to be in good standing in every state it dispenses into.
- A prescribing network with real state coverage. Physician licensure in every state the platform ships into — not a single doctor in one state writing for the entire country.
- A written agreement between the platform and the pharmacy that defines responsibility for prescribing, dispensing, dispensing records, adverse-event reporting, and patient communications.
Platforms that haven’t worked this out yet should not be sourcing peptide raw material yet. We will tell you that on the first call, and we will point you to the kind of advisor who can help you build the structure properly — but we will not open the supply relationship until the structure is real.
What we ship to the partner pharmacy.
Bulk peptide API for 503A compounding
Bulk active pharmaceutical ingredient with full chain-of-custody documentation, sized for the partner pharmacy’s 503A compounding workflow. FDA bulks list compliance considerations are part of the channel conversation.
503B finished-dose where the model supports it
For platform models that operate inside a licensed clinical setting — for example, a partner clinic that administers under office-use rules — 503B finished-dose can be the right format. The platform can’t ship 503B finished dose direct to a consumer’s home; the model has to route through a clinical setting.
Documentation built for two reviewers
The pharmacy QA reviewer wants identity, HPLC purity, endotoxin, and chain-of-custody. The platform’s legal reviewer wants to know that the supply-side relationship is documented, that the pharmacy is the customer, and that the platform’s liability surface is not exposed by an under-documented supply chain. Both get the documentation they need.
Lead time and re-order cadence.
The hard problem on the telehealth channel is volume volatility. A platform that runs a successful paid-media campaign can 3x its monthly dispense volume in two weeks; a platform that pauses media can drop to half. The partner pharmacy is the entity that actually carries that volatility, and we work with the pharmacy on reserved inventory and scheduled re-order cadence so the dispensing side is not constantly catching up.
For high-volume platforms with predictable monthly demand, we offer a scheduled program: reserved inventory at the manufacturing partner, monthly ship to the partner pharmacy, and a named account contact across both sides.
How the supply relationship is structured.
To set expectations on the model:
- Compounded finished product ships to the partner pharmacy as the dispensing entity, not to a fulfillment center.
- The platform’s prescribing network should reflect state-by-state physician coverage for the states the platform ships into — we will help you map the supply side to that footprint.
- The pharmacy is our wholesale customer of record; the platform is the integration partner. Where that structure is in place, we move fast.
We supply a wide range of telehealth platforms across the peptide market. Wholesale account approval is reviewed case-by-case based on facility documentation and intended use, with the goal of building a long-term, predictable supply relationship for the partner pharmacy.
Read next
- 503A vs 503B Peptide Sourcing: What Clinics and Pharmacies Need to Know
- Bulk API Sourcing: Chain of Custody Documentation Every Pharmacy Needs
- The FDA 503A Bulks List Explained
Frequently asked questions
We sell to the licensed pharmacy partner that operates as the dispensing entity for the platform. The pharmacy holds the supplier relationship, places orders under its license, and dispenses the finished compounded product on a valid prescription. The platform itself is our integration partner; the pharmacy is our customer.
Three things: (1) a partner 503A pharmacy with appropriate state licensure, (2) a prescribing network or medical group with state-by-state physician coverage for the states you ship to, and (3) a written agreement between the platform and the pharmacy that defines who is responsible for what. Account approval is reviewed case-by-case; once those three are in place, onboarding moves quickly.
In some platform models, yes — 503B finished-dose can be supplied to a licensed clinic that operates inside the telehealth model and administers under office-use rules. The finished-dose channel does not support direct shipment to consumers; the model has to route through a licensed clinical setting.
We ship to the partner pharmacy, not to consumers. The pharmacy is responsible for the state-by-state dispensing rules under its own license. We document where our material is going and confirm the pharmacy’s licensure is current in the receiving state; the dispensing-side state coverage itself is the pharmacy partner’s call.
Cataloged bulk API ships to the pharmacy in 5–10 business days from PO. Larger campaign orders or atypical specifications require a manufacturing slot — usually 4–8 weeks. For platforms with predictable monthly demand, we offer scheduled re-order cadence with reserved inventory so the dispensing pharmacy is not chasing supply.